Amanda Klein

Bio

Amanda Klein, PharmD, serves as the Executive Director for the Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) and the Critical Path for Lysosomal Diseases (CPLD) at the Critical Path Institute (C-Path). In her role, Dr. Klein leads pre-competitive collaboration among stakeholders aimed at accelerating the drug development process and addressing unmet needs prioritized within the consortia. Moreover, she champions rare diseases drug development by leading the Mitochondrial and Inherited Metabolic Diseases Task Force, a pivotal component of the RDCA-DAP initiative. This task force is instrumental in establishing an aggregated database and devising regulatory-grade solutions derived from its data, including innovative drug development tools.

Dr. Klein received a Bachelor of Science in nutritional sciences and a Doctor of Pharmacy from the University of Arizona. She further honed her expertise through residencies at the Phoenix VA Health Care System, specializing in ambulatory care and mental health. As a Clinical Instructor within the Department of Pharmacy Practice and Science at the College of Pharmacy, and as a designated campus colleague with the University of Arizona, Dr. Klein is deeply committed to nurturing the next generation of healthcare professionals.

Beyond academia, Dr. Klein is an engaged member of the American Pharmacists Association, actively contributing to the Care of Underserved Patients Advocacy Committee. She also serves as an Advisory Commissioner for the Arizona Health Education Center System and is a valued member of the American Diabetes Association’s esteemed Overcoming Therapeutic Inertia workgroup. Dr. Klein’s professional interests encompass a wide array of areas, including polypharmacy, non-communicable disease management, rural health, operational excellence, and integrative care, reflecting her multifaceted dedication to advancing healthcare on both local and global scales.